Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid Sparing Agent.

[1]  D. Okada,et al.  Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. , 2020, Journal of cardiac failure.

[2]  C. Torp‐Pedersen,et al.  Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. , 2020, Journal of the American College of Cardiology.

[3]  S. Shoor,et al.  TNF-alpha inhibition for the treatment of cardiac sarcoidosis. , 2019, Seminars in arthritis and rheumatism.

[4]  E. Mittra,et al.  Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. , 2019, Journal of cardiac failure.

[5]  E. Chen,et al.  The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment , 2017, Chest.

[6]  L. Cooper,et al.  Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring , 2017, Journal of Nuclear Cardiology.

[7]  F. Terasaki,et al.  New Guidelines for Diagnosis of Cardiac Sarcoidosis in Japan , 2017 .

[8]  M. Miyagawa,et al.  Japanese Guidelines for Cardiac Sarcoidosis , 2017 .

[9]  Amit R. Patel,et al.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. , 2017, JACC. Cardiovascular imaging.

[10]  M. Pomper,et al.  Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis. , 2017, JACC. Cardiovascular imaging.

[11]  R. Borie,et al.  Treatment of neurosarcoidosis , 2016, Neurology.

[12]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[13]  M. Becich,et al.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study. Sarcoidosis Protocol. , 2015, Annals of the American Thoracic Society.

[14]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[15]  C. Rose,et al.  Efficacy of mycophenolate mofetil in sarcoidosis. , 2014, Respiratory medicine.

[16]  D. Moller.  Negative clinical trials in sarcoidosis: failed therapies or flawed study design? , 2014, European Respiratory Journal.

[17]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[18]  M. Fishbein,et al.  Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment , 2014, Seminars in Respiratory and Critical Care Medicine.

[19]  A. Prasse,et al.  Sarcoidosis , 2014, The Lancet.

[20]  P. Nery,et al.  Corticosteroid therapy for cardiac sarcoidosis: a systematic review. , 2013, The Canadian journal of cardiology.

[21]  P. Zanen,et al.  Methotrexate vs azathioprine in second-line therapy of sarcoidosis. , 2013, Chest.

[22]  T. Geiser,et al.  Effect and Safety of Mycophenolate Mofetil in Chronic Pulmonary Sarcoidosis: A Retrospective Study , 2012, Respiration.

[23]  J. Parambil,et al.  Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis , 2011, European Respiratory Journal.

[24]  S. Vukusic,et al.  Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy , 2011, Neurology.

[25]  A. Burke,et al.  Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. , 2009, The American journal of cardiology.

[26]  J. Grutters,et al.  Corticosteroid treatment in sarcoidosis , 2006, European Respiratory Journal.

[27]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[28]  Y. Aizawa,et al.  Ventricular tachyarrhythmia associated with cardiac sarcoidosis: Its mechanisms and outcome , 2004, Clinical cardiology.

[29]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[30]  O. Vignaux,et al.  Detection of Myocardial Involvement in Patients with Sarcoidosis Applying T2-Weighted, Contrast-Enhanced, and Cine Magnetic Resonance Imaging: Initial Results of a Prospective Study , 2002, Journal of computer assisted tomography.

[31]  G. McLennan,et al.  Clinical characteristics of patients in a case control study of sarcoidosis. , 2001, American journal of respiratory and critical care medicine.

[32]  A. Perry,et al.  Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. , 1995, Archives of pathology & laboratory medicine.

[33]  Y. Kawabata,et al.  Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan , 1993, Acta pathologica japonica.

[34]  M. Cohen,et al.  Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. , 1991, Journal of the American College of Cardiology.

[35]  C. Johns,et al.  Longitudinal Study of Chronic Sarcoidosis with Low‐Dose Maintenance Corticosteroid Therapy , 1986, Annals of the New York Academy of Sciences.